StockNow
Calendar
Log in
Global Markets

Zealand Pharma (ZEAL DC) says Boehringer Ingelheim intends to conduct a regulatory submission for survodutide in 2027. Favourable cardiovascular safety supports the submission

ORIGINAL · NewsquawkZealand Pharma (ZEAL DC) says Boehringer Ingelheim intends to conduct a regulatory submission for survodutide in 2027. Favourable cardiovascular safety supports the submission
StockNow breaking-news AI analysis

Boehringer Ingelheim intends to submit survodutide for regulatory review in 2027, following Phase 3 cardiovascular-safety results and completion of the registrational SYNCHRONIZE program.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Nebius Group NV (NBIS) Q3 2026 (USD): Adj. EBITDA 465.8mln (exp. 351.8mln), Revenue 980.8mln (exp. 907.2mln)

NBISGeopolitics

US President Trump posts "We don’t need a deal with Iran. Those days have long since passed. We’ve got their money, Hundreds of Billions of Dollars, and we’ve got their Strait! Thank you for your attention to this matter."

U.S. Markets

Citrini's Jukan says that "One thing I’ve been able to confirm is that NVIDIA's (NVDA) Rubin has been delayed again. I’m told motherboard warpage caused the latest delay and that the HBM issue was resolved in October"

NVDA